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INTRODUCTION
Antineutrophil cytoplasmic antibody (ANCA)-associated vas-
culitis (AAV) is a typical systemic vasculitis involving small 
sized vessels. AAV mainly includes 3 variants, granulomatosis 
with polyangiitis (GPA), microscopic polyangiitis (MPA), and 
eosinophilic granulomatosis with polyangiitis (EGPA).1 De-
spite several differences in genetic backgrounds, aetiologies, 
ANCA type and histologic findings between GPA and MPA, 
these AAV variants exhibit similar clinical manifestations such 
as kidney, lung, and ear nose throat (ENT) involvements.2-4 Me-
anwhile, EGPA exhibits allergic features including asthma and 
eosinophilia.2,5 In the pathogenesis of AAV, various endogenous 
and exogenous factors trigger pro-inflammatory environment 
via activating circulating Th17 cells and macrophages, leading 
to priming neutrophils.6 Also, natural (homeostatic) ANCA can 
be converted into pathogenic ANCA by impaired B and T cells 
as well as enhanced B cell stimulation by ANCA activated neu-
trophils.7 Primed neutrophils bound to pathogenic ANCA sub-
sequently transmigrate into the vessel-adjacent tissues and pro-
voke inflammation.8 At this phase, neutrophil might be consum-
ed in the peripheral blood.
As the consumption of neutrophils increases, the number of 
immature granulocytes may be elevated. This is called the granu-
locytic shift to the left which usually reflects the enhanced pro-
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duction of granulocytes in bone marrow.9 In the clinical set-
tings, the immature granulocytes count has been widely used 
for infectious conditions. Leukocyte sub-fraction has been man-
ually counted, but currently is being automatically measured 
by subtracting the fraction of mature polymorphonuclear leu-
kocytes from the sum of myeloperoxidase (MPO)-reactive cells, 
which is called delta neutrophil index (DNI).10,11 DNI was re-
ported to be associated with neutrophil-consumption such as 
disseminated intravascular coagulation (DIC) scores or the mor-
tality of patients with sepsis.12,13 Moreover, we previously proved 
the clinical implication of DNI in differentiating rheumatic dis-
eases from infectious diseases.14-16 
In the pathogenesis of AAV, neutrophils and antibodies 
against neutrophils are important participants,7 and the imma-
ture granulocytes count can be theoretically elevated like DIC 
as AAV progress. Thus, it is reasonably speculated that DNI can 
reflect not only the extent of participation of neutrophil in the 
AAV pathogenesis, but also cross-sectional vasculitis activity of 
AAV. Furthermore, because the more neutrophils involved in 
the early phase of AAV may leave the more serious complica-
tions, we expected that DNI can predict poor prognosis of AAV 
during the follow-up. To the best of our knowledge, however, 
there was no report on the role of DNI in AAV. In this study, th-
erefore, we first investigated whether DNI might be associated 
with Birmingham vasculitis activity score (BVAS) at diagnosis and 
could predict relapse during the follow-up in patients with AAV.
MATERIALS AND METHODS
Patients
We retrospectively reviewed the electronic medical records of 
97 patients according to the inclusion criteria as follows: 1) pa-
tients who had been first classified as GPA, MPA, and EGPA 
from January 2010 to January 2017 at Department of Internal 
Medicine, Yonsei University College of Medicine, Severance 
Hospital; 2) those who had the results of DNI, which had been 
reported since January 2010 at our institute; 3) those who met 
the 1990 American College of Rheumatology criteria for GPA 
and EGPA, and who were reclassified as the same or another 
AAV by the 2007 European Medicine Agency algorithm and 
the 2012 Chapel Hill Consensus Conference criteria for all 
AAV;1,3-5 4) those who had the results of both MPO-ANCA and 
proteinase 3 (PR3)-ANCA by the enzyme-linked immunosor-
bent assay (ELISA) at diagnosis. Perinuclear (P)-ANCA and 
cytoplasmic (C)-ANCA were excluded to increase reliability in 
this study;17 5) those who had documented medical records 
clear enough to assess BVAS or BVAS for GPA, five factor score 
(FFS) (1996), and FFS (2009) at diagnosis;18-21 6) those who 
had no concomitant or previous medical conditions to confuse 
AAV classification, such as malignancies and serious infec-
tions, confirmed by the 10th revised International Classifica-
tion of Diseases; 7) those who had not received medications 
to affect ANCA positivity searched by the Korean Drug Utiliza-
tion Review (DUR) system. Twenty patients (20.6%) had GPA, 
58 (59.8%) had MPA and 19 (19.6%) had EGPA. This study was 
approved by the Institutional Review Board of Severance Hos-
pital (4-2017-0673).
Clinical data, BVAS, FFS and disease course
We obtained the demographic data such as age, gender, and 
the follow-up duration. We defined the follow-up duration as 
the period from diagnosis to the last visit of patients achieving 
remission without relapse. Meanwhile, we defined it as the 
period from diagnosis to the first relapse in patients with re-
lapse. We collected organ-based items of BVAS or BVAS for GPA 
as clinical data, assessed BVAS and BVAS for GPA, and calcu-
lated FFS (1996) and FFS (2009).18-21 In our study, BVAS implied 
both BVAS and BVAS for GPA. We also collected medications 
administered, which could influence the risk of relapse of GPA 
and MPA such as glucocorticoid, cyclophosphamide, myco-
phenolate mofetil, azathioprine, calcineurin inhibitor, metho-
trexate, and rituximab, during the follow-up or just prior to re-
lapse and compared those between patients with above and 
below the cut-off of DNI as described in Supplementary Table 
1 (only online) by under the Korean Drug Utilization Review 
(DUR) system. Remission was defined as absence of disease 
activity attributable to active disease qualified by the need for 
ongoing stable maintenance immunosuppressive therapy. Re-
lapse was defined as recurrence or new onset of disease attrib-
utable to active vasculitis after remission.22,23 
Laboratory data
We gathered laboratory data including white blood cell, haemo-
globin, RDW, prothrombin time (international normalised ra-
tio), fasting glucose, blood urea nitrogen, creatinine, protein, 
serum albumin, alkaline phosphatase, aspartate aminotrans-
ferase, alanine aminotransferase, total cholesterol, erythrocyte 
sedimentation rate (ESR), and C-reactive protein (CRP). Clini-
cal assessments were performed at the same day of blood tests. 
A specific type of automatic cell analyser (ADVIA 2120, Health-
care Diagnostics, Forchheim, Germany) was used to determine 
DNI as previously described.14-16 Our institution provides DNI 
as a part of routine complete blood count. MPO-ANCA and 
PR3-ANCA had been measured with ELISA kit for anti-PR3 
and anti-MPO (Inova Diagnostics, San Diego, CA, USA) before 
2013, and by the novel anchor coated highly sensitive (hs) Phad-
ia ELiA (Thermo Fisher Scientific/Phadia, Freiburg, Germany) 
using human native antigens, performed on a Phadia250 analy-
ser (Thermo Fisher Scientific/Phadia) after 2013.24,25
Statistical analysis 
All statistical analyses were conducted using SPSS software 
(version 23 for windows; IBM Corp., Armonk, NY, USA). Con-
tinuous variables were expressed as mean±standard devia-
tion, and categorical variables were done as number and the 
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percentage. The correlation coefficient between DNI and oth-
er continuous variables was obtained by the univariate Pear-
son’s correlation analysis. The standardised correlation coef-
ficient between BVAS and other continuous variables was 
assessed by the multivariate linear regression analysis using 
variables with significant differences in the univariate analysis. 
In this study, the highest quartile of BVAS was 20 or greater, 
and we defined MPA or GPA having BVAS ≥20 as severe AAV. 
The optimal cut-off of DNI was extrapolated via calculating 
the area under the receiver operator characteristic (AUROC) 
curve and selected when its sum of sensitivity and specificity 
was maximised. The relative risk (RR) of DNI under the initial 
BVAS ≥20 was evaluated using the contingency tables and the 
chi square analysis. The Kaplan-Meier survival analysis was 
used to analyse cumulative relapse free survival rate. p-values 
less than 0.05 were considered statistically significant.
RESULTS
Baseline characteristics
The baseline characteristics are summarised in Table 1. The 
Table 1. Baseline Characteristics of 97 Patients with ANCA-Associated 
Vasculitis 
Variables Values
Demographic data 
Age at diagnosis (yr)   59.4±15.2
Male gender 28 (28.9)
Follow-up duration (month)   49.8±46.4
Diagnosis
GPA 20 (20.6)
MPA 58 (59.8)
EGPA 19 (19.6)
Clinical manifestations at diagnosis
General manifestations 42 (43.3)
Cutaneous manifestations 23 (23.7)
Mucous membranes/eyes manifestations 5 (5.2)
Ear nose throat manifestations 34 (35.1)
Cardiovascular manifestations 26 (26.8)
Gastrointestinal manifestations 5 (5.2)
Pulmonary manifestations 54 (55.7)
Renal manifestations 59 (60.8)
Nervous systemic manifestations 21 (21.6)
BVAS and FFS at diagnosis
BVAS 12.7±7.5
FFS (1996) 0.9±1.0
FFS (2009) 1.7±0.9
ANCA type at diagnosis
MPO-ANCA 70 (72.1)
PR3-ANCA 15 (15.5)
ANCA negative 12 (12.4)
DNI at diagnosis (%)   1.5±2.2
Laboratory results at diagnosis
White blood cell (/mm3) 10348.8±4646.0
Haemoglobin (g/dL) 11.2±2.5
Platelet×103 (/mm3)   311.9±116.2
Prothrombin time (INR) (n=116)   1.0±0.1
Fasting glucose (mg/dL) 120.1±43.1
Blood urea nitrogen (mg/dL)   28.2±24.2
Creatinine (mg/dL)   1.9±2.1
Protein (mg/dL)   6.6±1.0
Serum albumin (mg/dL)   3.5±0.8
Alkaline phosphatase (IU/L)   94.7±98.9
Aspartate aminotransferase (IU/L)   25.3±30.2
Alanine aminotransferase (IU/L)   25.3±30.2
Acute reactants at diagnosis
ESR (mm/hr)   64.0±35.8
CRP (mg/L)   43.1±60.9
Disease course
Relapse 28 (28.9)
ANCA, antineutrophil cytoplasmic antibody; GPA, granulomatosis with poly-
angiitis; MPA, microscopic polyangiitis; EGPA, eosinophilic granulomatosis 
with polyangiitis; BVAS, Birmingham vasculitis activity score; FFS, five factor 
score; MPO, myeloperoxidase; PR3, proteinase 3; DNI, delta neutrophil index; 
INR, international normalised ratio; ESR, erythrocyte sedimentation rate; 
CRP, C-reactive protein. 
Values are expressed as mean±standard deviation and number (%). 
Table 2. Correlation between Delta Neutrophil Index and Other Continuous 
Variables in 97 Patients with ANCA-Associated Vasculitis at Diagnosis
Variables
Correlation 
coefficient (R=β)
p value
Demographic data 
Age at diagnosis -0.026 0.802
Follow-up duration 0.108 0.291
BVAS and FFS at diagnosis
BVAS 0.333 0.001
FFS (1996) 0.191 0.061
FFS (2009) 0.164 0.108
Laboratory results at diagnosis
White blood cell 0.392 <0.001
Haemoglobin 0.141 0.170
Platelet 0.189 0.064
Prothrombin time (INR) (n=116) 0.094 0.424
Fasting glucose 0.226 0.026
Blood urea nitrogen -0.112 0.273
Creatinine -0.033 0.750
Protein -0.153 0.135
Serum albumin -0.139 0.174
Alkaline phosphatase 0.015 0.882
Aspartate aminotransferase 0.071 0.491
Alanine aminotransferase 0.127 0.216
Acute reactants at diagnosis
ESR 0.077 0.467
CRP 0.235 0.025
ANCA, antineutrophil cytoplasmic antibody; BVAS, Birmingham vasculitis ac-
tivity score; FFS, five factor score; INR, international normalised ratio; ESR, 
erythrocyte sedimentation rate; CRP, C-reactive protein.
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mean age of 97 patients [28 men (28.9%)] was 59.4 years, and 
the mean follow-up duration was 49.8 months. The most fre-
quent clinical manifestation was renal involvement (60.8%), 
followed by pulmonary (55.7%), general (43.3%), and ENT 
(35.1%) manifestations. The mean initial BVAS, FFS (1996), 
and FFS (2009) were 12.7, 0.9, and 1.7, respectively. MPO-ANCA 
was detected in 70 patients (72.1%) and PR3-ANCA was found 
in 15 patients (15.5%). The mean DNI was 1.5%. The mean ESR 
and CRP were 64.0 mm/hr and 43.1 mg/L, respectively. Twen-
ty-eight patients (28.9%) had relapse during the follow-up. 
Correlation between DNI and other continuous 
variables in 97 patients with AAV at diagnosis
DNI was significantly related to BVAS at diagnosis (r=0.333, p= 
0.001), and DNI was also significantly linked to white blood cell 
(r=0.392, p<0.001), fasting glucose (r=0.226, p=0.026), and CRP 
(r=0.235, p=0.025) (Table 2). 
Univariate and multivariate linear regression analyses 
of BVAS and other continuous variables in 97 patients 
with AAV at diagnosis
Univariate linear regression analysis showed that BVAS was 
significantly related to DNI (r=0.332, p=0.001). BVAS was also 
positively linked to blood urea nitrogen (r=0.251, p=0.013), cre-
atinine (r=0.222, p=0.029), and CRP (r=0.239, p=0.023), and 
was negatively linked to haemoglobin (r=-0.213, p=0.036), pro-
tein (r=-0.313, p=0.002), and serum albumin (r=-0.357, p< 
0.001). Although BVAS was significantly related to FFS (1996) 
(r=0.386, p<0.001), and FFS (2009) (r=0.802, p=0.047), FFS was 
excluded in multivariate linear regression analysis due to the 
risk of multicollinearity between BVAS and FFS. Multivariate 
linear regression analysis indicated that only DNI among con-
tinuous variables was associated with BVAS with statistical 
significance in univariate linear regression analysis [β=0.312, 
95% confidence interval (CI) 0.359–1.780, p=0.004] (Table 3).
Table 3. Univariate and Multivariate Linear Regression Analyses of BVAS and Other Continuous Variables in 97 Patients with ANCA-Associated Vas-
culitis at Diagnosis
Variables
Univariate analysis Multivariate analysis
Regression 
coefficient 
(Crude B)
Correlation  
coefficient 
(R=β)
p value Standardized β*
95% confidence 
interval
p value
Demographic data 
Age at diagnosis 0.027 0.055 0.592
Follow-up duration -0.037 -0.141 0.169
FFSs at diagnosis*
FFS (1996) 3.049 0.386 <0.001
FFS (2009) 3.888 0.802 <0.001
DNI at diagnosis 1.146 0.332 0.001 0.312 0.359–1.780 0.004
Laboratory results at diagnosis
White blood cell 0.000 0.130 0.205
Haemoglobin -0.646 -0.213 0.036 0.012 -0.753–0.825 0.928
Platelet 0.007 0.106 0.301
Prothrombin time (INR) (n=59) 11.146 0.204 0.080
Fasting glucose 0.015 0.086 0.400
Blood urea nitrogen 0.078 0.251 0.013 0.174 -0.033–0.142 0.221
Creatinine 0.804 0.222 0.029 0.098 -0.621–1.345 0.466
Protein -2.482 -0.313 0.002 -0.025 -2.275–1.876 0.849
Serum albumin -3.504 -0.357 <0.001 -0.250 -5.573–0.515 0.102
Alkaline phosphatase 0.008 0.112 0.275
Aspartate aminotransferase 0.039 0.159 0.120
Alanine aminotransferase 0.037 0.164 0.109
Acute reactants at diagnosis
ESR 0.040 0.187 0.075
CRP 0.030 0.239 0.023 0.008 -0.028–0.030 0.948
BVAS, Birmingham vasculitis activity score; ANCA, antineutrophil cytoplasmic antibody; FFS, five factor score; DNI, delta neutrophil index; INR, international 
normalised ratio; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein. 
*We did not include FFS (1996) and FFS (2009) in multivariate linear regression analysis due to the risk of multicollinearity between BVAS and FFS. 
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Correlation between DNI and other continuous 
variables in 78 patients with GPA and MPA 
at diagnosis
We conducted sub-group analyses in each variant of AAV. DNI 
was significantly related to BVAS in patients with GPA (r= 
0.730, p<0.001) and MPA (r=0.290, p=0.027), but not in those 
with EGPA (r=0.415, p=0.078). Therefore, we excluded patients 
with EGPA and reanalysed the association of DNI with BVAS 
at diagnosis in 78 patients with MPA and GPA. DNI was signif-
icantly related to BVAS (r=0.351, p=0.002). It was also signifi-
cantly linked to white blood cell (r=0.245, p=0.031), fasting glu-
cose (r=0.363, p=0.001), and CRP (r=0.248, p=0.036), and was 
inversely linked to protein (r=-0.291, p=0.010) and serum albu-
min (r=-0.224, p=0.049) (Table 4). 
Univariate and multivariate linear regression analyses 
of BVAS and other continuous variables in 78 patients 
with GPA and MPA at diagnosis
Univariate linear regression analysis exhibited that BVAS was 
significantly related to DNI (r=0.351, p=0.002). BVAS was also 
positively linked to blood urea nitrogen (r=0.254, p=0.025) and 
was negatively linked to the follow-up duration (r=-0.270, p= 
0.017), protein (r=-0.308, p=0.006), and serum albumin (r= 
-0.314, p=0.005). However, BVAS was not linked to ESR or CRP. 
FFS was excluded in multivariate linear regression analysis due 
to the risk of multicollinearity between BVAS and FFS. Multi-
variate linear regression analysis indicated that only DNI 
among continuous variables was associated with BVAS with 
statistical significance in univariate linear regression analysis 
(β=0.276, 95% CI 0.271–2.140, p=0.012) (Table 5).
The optimal cut-off of DNI to identify severe AAV in 
78 patients with GPA and MPA at diagnosis
We divided patients with GPA and MPA into the two groups 
according to the cut-off of severe AAV. Seventeen patients 
(21.8%) had BVAS ≥20 and belonged to severe AAV group. We 
calculated the optimal cut-off of DNI to identify severe AAV, 
and found that 0.65% was a strong measurement of severe AAV 
(AUROC 0.664, 95% CI 0.516–0.813, p=0.039; sensitivity 70.6% 
and specificity 63.9%). We also divided 78 patients with GPA 
and MPA into the two groups according to the optimal cut-off 
of DNI. There were no significant differences in medications 
administered during the follow-up or prior to relapse between 
patients having DNI ≥0.65% and those having DNI <0.65% 
(Supplementary Table 1, only online). Severe AAV was identi-
fied more often in patients having DNI ≥0.65% than those hav-
ing DNI <0.65% (35.3% vs. 11.4%, p=0.011) (Fig. 1A). Moreover, 
patients having DNI ≥0.65% had a significantly higher risk of 
severe AAV than those not having (RR 4.255, 95% CI 1.325–
13.665). 
DNI at diagnosis to predict relapse in 78 patients with 
GPA and MPA during follow-up
We evaluated whether DNI at diagnosis could predict relapse 
during the follow-up of patients with MPA and GPA. First, be-
cause DNI was significantly related to BVAS at diagnosis, and 
BVAS at diagnosis could predict poor prognosis during the fol-
low-up in previous studies,24,25 we calculated the optimal cut-
off of DNI at diagnosis to predict relapse of MPA and GPA, 
however, we could find no optimal cut-off (AUROC 0.460, p= 
0.589). Second, we divided 78 patients with GPA and MPA into 
the two groups according to the presence of relapse, and com-
pared DNI, BVAS, FFS (1996), and FFS (2009). Patients with 
relapse exhibited the higher mean BVAS and FFS (1996) than 
those without [17.5 vs. 10.8, p<0.001 for BVAS, and 1.3 vs. 0.7, 
p=0.013 for FFS (1996)]. However, DNI did not differ between 
the two groups (1.9 vs. 1.3, p=0.239). Last, because DNI ≥0.65% 
could identify severe AAV, we investigated its potential as a 
predictor of relapse using Kaplan-Meier survival analysis. Cu-
mulative relapse free survival rate was depicted in Fig. 1B. Ac-
cording to DNI ≥0.65% at diagnosis, there was a significant dif-
ference in cumulative relapse free survival rates between the 
two groups (p=0.029). 
Table 4. Correlation between Delta Neutrophil Index and Other Continu-
ous Variables in 78 Patients with Granulomatosis with Polyangiitis and 
Microscopic Polyangiitis at Diagnosis
Variables
Correlation 
coefficient (R=β)
p value
Demographic data 
Age at diagnosis 0.142 0.214
Follow-up duration -0.138 0.229
BVAS and FFS at diagnosis
BVAS 0.351 0.002
FFS (1996) 0.147 0.199
FFS (2009) 0.184 0.107
Laboratory results at diagnosis
White blood cell 0.245 0.031
Haemoglobin 0.061 0.598
Platelet 0.213 0.061
Prothrombin time (INR) 0.016 0.905
Fasting glucose 0.363 0.001
Blood urea nitrogen 0.000 0.997
Creatinine 0.024 0.833
Protein -0.291 0.010
Serum albumin -0.224 0.049
Alkaline phosphatase 0.072 0.531
Aspartate aminotransferase 0.022 0.846
Alanine aminotransferase 0.065 0.572
Acute reactants at diagnosis
ESR 0.081 0.494
CRP 0.248 0.036
BVAS, Birmingham vasculitis activity score; FFS, five factor score; INR, inter-
national normalised ratio; ESR, erythrocyte sedimentation rate; CRP, C-reac-
tive protein.
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Table 5. Univariate and Multivariate Linear Regression Analyses of BVAS and Other Continuous Variables in 78 Patients with Granulomatosis with 
Polyangiitis and Microscopic Polyangiitis at Diagnosis
Variables
Univariate analysis Multivariate analysis
Regression 
coefficient 
(Crude B)
Correlation 
coefficient 
(R=β)
p value Standardized β*
95% confidence 
interval
p value
Demographic data 
Age at diagnosis -0.004 -0.007 0.953
Follow-up duration -0.072 -0.270 0.017 -0.188 -0.106–0.005 0.073
FFSs at diagnosis*
FFS (1996) 2.373 0.284 0.012
FFS (2009) 3.647 0.410 <0.001
DNI at diagnosis 1.529 0.351 0.002 0.276 0.271–2.140 0.012
Laboratory results at diagnosis
White blood cell 0.000 0.088 0.445
Haemoglobin -0.643 -0.199 0.080
Platelet 0.005 0.072 0.530
Prothrombin time (INR) (n=59) 10.616 0.201 0.135
Fasting glucose 0.021 0.123 0.281
Blood urea nitrogen 0.076 0.254 0.025 0.058 -0.007–0.123 0.077
Creatinine 0.788 0.222 0.051
Protein -2.559 -0.308 0.006 -0.038 -2.738–2.112 0.798
Serum albumin -3.167 -0.314 0.005 -0.167 -4.449–1.072 0.227
Alkaline phosphatase 0.008 0.110 0.338
Aspartate aminotransferase 0.031 0.131 0.253
Alanine aminotransferase 0.029 0.135 0.237
Acute reactants at diagnosis
ESR 0.041 0.174 0.142
CRP 0.028 0.212 0.074
BVAS, Birmingham vasculitis activity score; FFS, five factor score; DNI, delta neutrophil index; INR, international normalised ratio; ESR, erythrocyte sedimenta-
tion rate; CRP, C-reactive protein. 
*We did not include FFS (1996) and FFS (2009) in multivariate linear regression analysis due to the risk of multicollinearity between BVAS and FFS. 
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Fig. 1. DNI identified severe AAV at diagnosis and predicted relapse of GPA and MPA during the follow-up. (A) Patients having DNI ≥0.65% had se-
vere AAV (BVAS ≥20) more frequently than those having DNI <0.65% (35.3% vs. 11.4%, p=0.011). (B) In Kaplan-Meier survival analysis, patients having 
DNI ≥0.65% exhibited lower cumulative relapse free survival rate than those having DNI <0.65% (p=0.029). DNI, delta neutrophil index; AAV, antineu-
trophil cytoplasmic antibody-associated vasculitis; GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiitis; BVAS, Birmingham vasculi-
tis activity score; RR, relative risk.
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DISCUSSION
In this study, we first reported that DNI was associated with 
BVAS at diagnosis and could predict relapse during the follow-
up in patients with AAV. DNI was remarkably related to BVAS 
and furthermore, among continuous variables, only DNI could 
reflect BVAS at diagnosis in not only all patients with AAV, but 
also patients with GPA and MPA. However, because the associ-
ation of DNI with BVAS was not apparent in patients with 
EGPA, we selected the results on patients with only GPA and 
MPA. In addition, we provided the optimal cut-off of DNI of 
0.65% for identifying severe AAV based on BVAS, and found 
that patients having DNI ≥0.65% had significantly higher risk 
of severe AAV (GPA and MPA) than those not having (RR 4.255) 
at diagnosis. On the other hands, we applied DNI ≥0.65% to pre-
dict relapse of GPA and MPA during the follow-up, and found 
a significant difference in cumulative relapse free survival be-
tween the two groups according to DNI ≥0.65% (p=0.029). We, 
therefore, concluded that DNI could reflect BVAS at diagnosis 
and furthermore, DNI ≥0.65% could not only identify severe 
AAV at diagnosis, but also predict relapse during the follow-up 
in patients with GPA and MPA. 
How can DNI reflect BVAS? Based on the pathogenesis of 
AAV, we assume the link between DNI and BVAS as follows: 1) 
various aetiologies drive T cells and macrophages to produce 
inflammatory cytokines, which can prime neutrophils, leading 
to an increase in adhesion molecules and ANCA antigens on 
their surface;26-28 2) this inflammatory conditions also increase 
adhesion molecules on endothelial cells;29 3) the ANCA-me-
diated interaction between primed neutrophils and activated 
endothelial cells occurs, and activated neutrophils migrate be-
yond vascular walls;30 4) complement pathway also accelerates 
the ANCA-associated activation of neutrophils;31,32 5) finally, 
activated neutrophils provoke vasculitis by reactive oxygen 
radicals and degranulation.7,8,33 Therefore, neutrophils partici-
pating in inflammation may be gradually consumed and the 
number of immature neutrophils increases. With this hypoth-
esis, we speculate that DNI can reflect BVAS of AAV.
Although DNI at diagnosis ≥0.65% significantly reduced cu-
mulative relapse free survival compared with DNI at diagnosis 
<0.65% in Kaplan-Meier survival analysis, we failed to obtain 
the optimal cut-off of DNI at diagnosis to predict relapse of GPA 
and MPA during the follow-up in AUROC analysis. We recently 
have reported the predictive value of BVAS at diagnosis for re-
lapse of AAV and polyarteritis nodosa.24,25,34 With this concept, 
we compared the potential of DNI with BVAS at diagnosis for 
predicting relapse of GPA and MPA during the follow-up. We 
calculated the optimal cut-off of BVAS at diagnosis to predict 
relapse using AUROC, and found that 15.5 of BVAS had the 
strongest predictive value (AUROC 0.746, 95% CI 0.618–0.874, 
p=0.001; sensitivity 66.7% and specificity 77.2%). Also, we found 
that patients having BVAS at diagnosis ≥15.5 had the lower cu-
mulative relapse free survival than those not having (p<0.001). 
Moreover, we conducted a Cox Hazard model using DNI ≥0.65% 
and BVAS ≥15.5 at diagnosis to predict relapse. Before a Cox 
Hazard analysis, we investigated the multicollinearity between 
DNI ≥0.65 and BVAS ≥15.5 using a multivariate linear regres-
sion test, and found no significant multicollinearity (variance 
inflation factor was 1.140). When we performed a Cox Hazard 
model using those two variables, we found that only BVAS ≥15.5 
showed the predictive significance for relapse (odds ratio 
6.174, 95% CI 2.268–16.805, p<0.001). Although DNI ≥0.65% 
showed a significant predictive potential for relapse in Kaplan-
Meier survival analysis, it could not surpass that of BVAS at di-
agnosis ≥15.5. 
We studied the reason of why the predictive potential of DNI 
could not reach that of BVAS at diagnosis and suggested that 
DNI is the current progressive type, while BVAS is the current 
completion type. In the putative sequence of the pathogenesis 
of AAV, neutrophil priming and activation through loss of toler-
ance of T and B cells and ANCA autoimmune response initiates 
acute injury.7,33 At this phase, most participants are neutrophils. 
Meanwhile, the next step switches on innate immunity re-
sponses, leading to either resolution or sclerotic progress in-
cluding granulomatosis formation. At this phase, most partici-
pants are lymphocytes and macrophages.8 Because DNI is 
closely linked to the consumption of mature neutrophils, DNI 
might be predominantly associated with neutrophil-predom-
inant phase, whereas BVAS might be predominantly associat-
ed with irreversible sclerotic phase. In addition, relapse be-
gins new and acute autoimmune responses on the basis of 
established chronic sclerosis, fibrosis, and granulomatosis 
more often than on that of normal tissues. Not a few patients 
are classified as AAV at chronic irreversible sclerotic phase 
rather than at acute neutrophil-predominant phase. Thus, BVAS 
at diagnosis occupies larger phases in the putative sequence 
of the pathogenesis of AAV than DNI at diagnosis, and BVAS 
at diagnosis can predict relapse of GPA and MPA better than 
DNI at diagnosis. On the contrary, because the higher level of 
DNI at diagnosis implies more likely phase to heal and return 
to normal tissues, we suggests that patients having high DNI 
at diagnosis should receive more immediate and aggressive 
treatment. 
Our present study has a strong advantage in that we first 
proved the association of DNI with BVAS at diagnosis and 
provided the optimal cut-off of DNI to predict relapse during 
the follow-up in patients with GPA and MPA. However, our 
study has also several limitations. First, we could not clarify the 
mechanism of the association of DNI and BVAS and its pre-
dictive value for relapse. Second, because DNI has been report-
ed since January 2010, the number of patients was not large 
enough to enhance reliability. Last, due to a retrospective de-
sign of this study and lack of information on serial BVAS dur-
ing the follow-up duration, we could not clarify the link be-
tween changes of DNI and BVAS over time. Thus, prospective 
studies with a larger number of patients are required to obtain 
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more reliable information on the role of DNI in AAV. 
In conclusion, DNI could reflect BVAS at diagnosis and fur-
thermore, DNI ≥0.65% could not only identify severe AAV at 
diagnosis, but also predict relapse during the follow-up in pa-
tients with GPA and MPA. 
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